[1] ASHLEY S, BRADBURN S, MURGATROYD C. A meta-analysis of peripheral tocopherol levels in age-related cognitive decline and Alzheimer's disease. Nutr Neurosci. 2019. doi:10.1080/1028415X.2019.1681066.
[2] Alzheimer’s Disease International. World Alzheimer Report 2015: The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Costand Trends. London: Alzheimer’s Disease International, 2015 [2019-03-07]. https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf.
[3] MORTON RE, ST JOHN PD, TYAS SL. Migraine and the risk of all-cause dementia, Alzheimer's disease, and vascular dementia: A prospective cohort study in community-dwelling older adults. Int J Geriatr Psychiatry. 2019;34(11):1667-1676.
[4] STOCKER H, NABERS A, PERNA L, et al. Prediction of Alzheimer's disease diagnosis within 14 years through Aβ misfolding in blood plasma compared to APOE4 status, and other risk factors. Alzheimers Dement. 2019. doi:10.1016/j.jalz.2019.08.189.
[5] XU W, TAN L, WANG HF, et al. Education and Risk of Dementia: Dose-Response Meta-Analysis of Prospective Cohort Studies. Mol Neurobiol. 2016;53(5):3113-3123.
[6] WASHINGTON PM, VILLAPOL S, BURNS MP. Polypathology and dementia after brain trauma: Does brain injury trigger distinct neurodegenerative diseases, or should they be classified together as traumatic encephalopathy?. Exp Neurol. 2016;275 Pt 3(0 3):381-388.
[7] MASTERS CL, SIMMS G, WEINMAN NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82(12):4245-4249.
[8] LEE VM, GOEDERT M, TROJANOWSKI JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121-1159.
[9] SEABROOK TJ, THOMAS K, JIANG L, et al. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol Aging. 2007;28(6):813-823.
[10] BOHRMANN B, BAUMANN K, BENZ J, et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis. 2012;28(1):49-69.
[11] KIM SH, CARNEY DF, HAMMER CH, et al. Nucleated cell killing by complement: effects of C5b-9 channel size and extracellular Ca2+ on the lytic process. J Immunol. 1987;138(5):1530-1536.
[12] ROGERS J, COOPER NR, WEBSTER S, et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A. 1992; 89(21):10016-10020.
[13] YANG LB, LI R, MERI S, et al. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J Neurosci. 2000;20(20):7505-7509.
[14] YANG L, LINDHOLM K, KONISHI Y, et al. Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J Neurosci. 2002;22(8):3025-3032.
[15] SHEN Y, YANG L, LI R. What does complement do in Alzheimer's disease? Old molecules with new insights. Transl Neurodegener. 2013;2(1):21.
[16] LIAN H, YANG L, COLE A, et al. NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease. Neuron. 2015;85(1):101-115.
[17] KRSTIC D, KNUESEL I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol. 2013;9(1):25-34.
[18] MCGEER PL, MCGEER EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013;126(4):479-497.
[19] SPIRES-JONES T, KNAFO S. Spines, plasticity, and cognition in Alzheimer's model mice. Neural Plast. 2012;2012:319836.
[20] TOSUN D, JOSHI S, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Neuroimaging predictors of brain amyloidosis in mild cognitive impairment. Ann Neurol. 2013;74(2):188-198.
[21] SELKOE DJ. Alzheimer's disease is a synaptic failure. Science. 2002; 298(5594):789-791.
[22] VOSSEL KA, ZHANG K, BRODBECK J, et al. Tau reduction prevents Abeta-induced defects in axonal transport. Science. 2010;330(6001): 198.
[23] SCHMITT K, GRIMM A, KAZMIERCZAK A, et al. Insights into mitochondrial dysfunction: aging, amyloid-β, and tau-A deleterious trio. Antioxid Redox Signal. 2012;16(12):1456-1466.
[24] YAMADA M. [Senile Dementia of the Neurofibrillary Tangle Type (SD-NFT)]. Brain Nerve. 2018;70(5):533-541.
[25] HUBER CM, YEE C, MAY T, DHANALA A, MITCHELL CS. Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy. J Alzheimers Dis. 2018;61(1):265-281.
[26] IQBAL K, LIU F, GONG CX. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol. 2016;12(1):15-27.
[27] ZEMPEL H, MANDELKOW E. Lost after translation: missorting of Tau protein and consequences for Alzheimer disease. Trends Neurosci. 2014;37(12):721-732.
[28] YAMADA K, PATEL TK, HOCHGRÄFE K, et al. Analysis of in vivo turnover of tau in a mouse model of tauopathy. Mol Neurodegener. 2015;10:55.
[29] CABRALES FONTELA Y, KADAVATH H, BIERNAT J, et al. Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau. Nat Commun. 2017;8(1):1981.
[30] ZHOU L, MCINNES J, WIERDA K, et al. Tau association with synaptic vesicles causes presynaptic dysfunction. Nat Commun. 2017;8:15295.
[31] BARDAI FH, WANG L, MUTREJA Y, et al. A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations In Vivo. J Neurosci. 2018;38(1):108-119.
[32] MATSUO ES, SHIN RW, BILLINGSLEY ML, et al. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron. 1994;13(4): 989-1002.
[33] GÓMEZ-ISLA T, HOLLISTER R, WEST H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997;41(1):17-24.
[34] GOEDERT M, KLUG A, CROWTHER RA. Tau protein, the paired helical filament and Alzheimer's disease. J Alzheimers Dis. 2006; 9(3 Suppl):195-207.
[35] DE CALIGNON A, POLYDORO M, SUÁREZ-CALVET M, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73(4):685-697.
[36] CLAVAGUERA F, BOLMONT T, CROWTHER RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11(7):909-913.
[37] LI B, CHOHAN MO, GRUNDKE-IQBAL I, et al. Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau. Acta Neuropathol. 2007;113(5):501-511.
[38] AMNIAI L, BARBIER P, SILLEN A, et al. Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules. FASEB J. 2009;23(4):1146-1152.
[39] SMALL SA, DUFF K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron. 2008;60(4):534-542.
[40] MCGOWAN E, ERIKSEN J, HUTTON M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 2006;22(5): 281-289.
[41] ZHANG YW, THOMPSON R, ZHANG H, et al. APP processing in Alzheimer's disease. Mol Brain. 2011;4:3.
[42] SCHONROCK N, MATAMALES M, ITTNER LM, et al. MicroRNA networks surrounding APP and amyloid-β metabolism--implications for Alzheimer's disease. Exp Neurol. 2012;235(2):447-454.
[43] BENILOVA I, KARRAN E, DE STROOPER B. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci. 2012;15(3):349-357.
[44] ZHENG YL, KESAVAPANY S, GRAVELL M, et al. A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. EMBO J. 2005;24(1):209-220.
[45] DEBELJUH N, BARROW CJ, HENDERSON L, et al. Structure inducing ionic liquids-enhancement of alpha helicity in the Abeta(1-40) peptide from Alzheimer's disease. Chem Commun (Camb). 2011;47(22):6371-6373.
[46] GARZON-RODRIGUEZ W, SEPULVEDA-BECERRA M, MILTON S, et al. Soluble amyloid Abeta-(1-40) exists as a stable dimer at low concentrations. J Biol Chem. 1997;272(34):21037-21044.
[47] CLEARY JP, WALSH DM, HOFMEISTER JJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8(1):79-84.
[48] CHIANG ACA, FOWLER SW, REDDY R, et al. Discrete Pools of Oligomeric Amyloid-β Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis. Am J Pathol. 2018;188(3):739-756.
[49] GOÑI F, MARTÁ-ARIZA M, HERLINE K, et al. Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer's disease model. Alzheimers Res Ther. 2018;10(1):10.
[50] RUSBRIDGE C, SALGUERO FJ, DAVID MA, et al. An Aged Canid with Behavioral Deficits Exhibits Blood and Cerebrospinal Fluid Amyloid Beta Oligomers. Front Aging Neurosci. 2018;10:7.
[51] SUN L, ZHONG Y, GUI J, et al. A hydrogel biosensor for high selective and sensitive detection of amyloid-beta oligomers. Int J Nanomedicine. 2018;13:843-856.
[52] LAFERLA FM, GREEN KN, ODDO S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007;8(7):499-509.
[53] KAM TI, GWON Y, JUNG YK. Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer's disease. Cell Mol Life Sci. 2014;71(24):4803-4813.
[54] RAPOPORT M, DAWSON HN, BINDER LI, et al. Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A. 2002; 99(9):6364-6369.
[55] ROBERSON ED, SCEARCE-LEVIE K, PALOP JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316(5825):750-754.
[56] SEINO Y, KAWARABAYASHI T, WAKASAYA Y, et al. Amyloid β accelerates phosphorylation of tau and neurofibrillary tangle formation in an amyloid precursor protein and tau double-transgenic mouse model. J Neurosci Res. 2010;88(16):3547-3554.
[57] NUSSBAUM JM, SCHILLING S, CYNIS H, et al. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. Nature. 2012;485(7400):651-655.
[58] SUN L, WANG X, LIU S, et al. Bilateral injection of isoproterenol into hippocampus induces Alzheimer-like hyperphosphorylation of tau and spatial memory deficit in rat. FEBS Lett. 2005;579(1):251-258.
[59] XU G, GONZALES V, BORCHELT DR. Abeta deposition does not cause the aggregation of endogenous tau in transgenic mice. Alzheimer Dis Assoc Disord. 2002;16(3):196-201.
[60] ODDO S, CACCAMO A, SHEPHERD JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39(3):409-421.
[61] AMADORO G, CORSETTI V, CIOTTI MT, et al. Endogenous Aβ causes cell death via early tau hyperphosphorylation. Neurobiol Aging. 2011;32(6):969-990.
[62] ODDO S, VASILEVKO V, CACCAMO A, et al. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem. 2006;281(51):39413-39423.
[63] ZEMPEL H, THIES E, MANDELKOW E, et al. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci. 2010;30(36):11938-11950.
[64] JIN M, SHEPARDSON N, YANG T, et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A. 2011;108(14):5819-5824.
[65] SHIPTON OA, LEITZ JR, DWORZAK J, et al. Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci. 2011;31(5):1688-1692.
[66] BOUTAJANGOUT A, QUARTERMAIN D, SIGURDSSON EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci. 2010;30(49):16559-16566.
[67] ITTNER LM, KE YD, DELERUE F, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010;142(3):387-397.
[68] HAASS C, MANDELKOW E. Fyn-tau-amyloid: a toxic triad. Cell. 2010; 142(3):356-358.
[69] KAM TI, SONG S, GWON Y, et al. FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer's disease. J Clin Invest. 2013;123(7):2791-2802.
[70] RESENDE R, FERREIRO E, PEREIRA C, et al. ER stress is involved in Abeta-induced GSK-3beta activation and tau phosphorylation. J Neurosci Res. 2008;86(9):2091-2099.
[71] KIM T, VIDAL GS, DJURISIC M, et al. Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science. 2013;341(6152):1399-1404.
[72] TERWEL D, MUYLLAERT D, DEWACHTER I, et al. Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol. 2008;172(3):786-798.
[73] STANCU IC, VASCONCELOS B, TERWEL D, et al. Models of β-amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism. Mol Neurodegener. 2014;9:51.
[74] FEIN JA, SOKOLOW S, MILLER CA, et al. Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes. Am J Pathol. 2008;172(6):1683-1692.
[75] TAKAHASHI RH, CAPETILLO-ZARATE E, LIN MT, et al. Co-occurrence of Alzheimer's disease ß-amyloid and τ pathologies at synapses. Neurobiol Aging. 2010;31(7):1145-1152.
[76] MILLER Y, MA B, NUSSINOV R. Synergistic interactions between repeats in tau protein and Aβ amyloids may be responsible for accelerated aggregation via polymorphic states. Biochemistry. 2011;50(23):5172-5181.
[77] GUO JP, ARAI T, MIKLOSSY J, et al. Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103(6):1953-1958.
[78] IIJIMA K, GATT A, IIJIMA-ANDO K. Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease. Hum Mol Genet. 2010;19(15): 2947-2957.
[79] YOSHIYAMA Y, LEE VM, TROJANOWSKI JQ. Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry. 2013;84(7):784-795.
[80] ROSENBERG RN, FU M, LAMBRACHT-WASHINGTON D. Active full-length DNA Aβ42 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology. Alzheimers Res Ther. 2018; 10(1):115.
[81] JADHAV S, AVILA J, SCHÖLL M, et al. A walk through tau therapeutic strategies. Acta Neuropathol Commun. 2019;7(1):22.
[82] VITALE F, GILIBERTO L, RUIZ S, et al. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice. Acta Neuropathol Commun. 2018;6(1):82.
[83] NOVAK P, SCHMIDT R, KONTSEKOVA E, et al. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease. Alzheimers Res Ther. 2018;10(1):108.
|